Olivier Spertini

Lausanne, VD, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature.

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature.

Journal: Swiss medical weekly

Published: January 29, 2025

Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen.

Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: January 08, 2025

Macrophage migration inhibitory factor blockade reprograms macrophages and disrupts prosurvival signaling in acute myeloid leukemia.

Macrophage migration inhibitory factor blockade reprograms macrophages and disrupts prosurvival signaling in acute myeloid leukemia.

Journal: Cell death discovery

Published: September 29, 2023

Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.

Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.

Journal: Hematology (Amsterdam, Netherlands)

Published: February 23, 2023

Comparative analysis of automated cell counts in oncological patients: Reliable results of point of care blood impedance measurements and pitfalls in myelodysplastic neoplasias and acute myeloid leukemias.

Comparative analysis of automated cell counts in oncological patients: Reliable results of point of care blood impedance measurements and pitfalls in myelodysplastic neoplasias and acute myeloid leukemias.

Journal: International journal of laboratory hematology

Published: February 01, 2023

MarrowQuant 2.0: A Digital Pathology Workflow Assisting Bone Marrow Evaluation in Experimental and Clinical Hematology.

MarrowQuant 2.0: A Digital Pathology Workflow Assisting Bone Marrow Evaluation in Experimental and Clinical Hematology.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: July 15, 2022

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.

Journal: Leukemia

Published: May 24, 2022

Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.

Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.

Journal: Haematologica

Published: April 28, 2022

High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.

High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: December 10, 2021

Isolated skin infiltration by a blastic plasmacytoid dendritic cell neoplasm.

Isolated skin infiltration by a blastic plasmacytoid dendritic cell neoplasm.

Journal: EJHaem

Published: October 14, 2021

Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript.

Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript.

Journal: Biomarker research

Published: October 08, 2021

Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia.

Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia.

Journal: American journal of hematology

Published: October 04, 2021

Showing 1-12 of 43

Last Updated: 09/26/2026